Lipid Transport Disorder Italian Genetic Record (LIPIGEN)

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorFondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi)

About this trial

LIPIGEN is an observational study involving Italian physicians and researchers in the field of diseases related to blood lipid levels. This study aims to improve the diagnosis and treatment of people with familial dyslipidaemias, including very common conditions such as familial hypercholesterolaemia (FH) and less common ones such as familial chylomicronidaemic syndrome (FCS).

What does the study do?

It collects information on Italian patients with Familial Hypercholesterolaemia (FH), following them in their normal clinical examination without adding extra procedures.

It uses the data collected to further our understanding of diseases such as familial hypercholesterolaemia, examining how it is diagnosed clinically and by genetic testing, and evaluating the effectiveness of different treatments.

It seeks to identify the genetic mutations that cause familial hypercholesterolaemia and other dyslipidaemias, helping to choose the most effective treatments.

It evaluates the impact of long-term treatments and patient adherence to medication, as well as monitoring the incidence of cardiovascular events and other important outcomes.

Who can participate?

The study is aimed at people of all ages, from children to adults, with familial hypercholesterolaemia or other genetic dyslipidaemia.

More than 50 centres throughout Italy are involved, making the study accessible to many.

What does participation entail?

Participants will continue with their normal clinical practice.

Data such as family history, personal clinical findings and genetic information will be collected, without additional procedures.

For some, further evaluations, such as ultrasounds, may be required to better study their condition.

The LIPIGEN study not only helps to better understand diseases related to high cholesterol but also aims to improve patients\' lives through more precise diagnosis and personalised treatments.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Molecular or clinical diagnosis of genetic dyslipidemia

Informed consent signed

Disqualifiers

None

Trial population

Subjects with molecular or clinical diagnosis of genetic dyslipidemia of any age or sex.

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • Lipid-lowering treatments

    Drug

Treatment groups

No treatment groups listed

Trial outcomes

Primary outcomes

1

Lipid profile of patients with genetic dyslipidemia

Lipid profile of patients with molecular or clinical diagnosis of genetic dyslipidemia: * LDL cholesterol (mg/dL) * Total cholesterol (mg/dL) * HDL cholesterol (mg/dL) * Triglycerides (mg/dL) * Lipoprotein (a) (mg/dL), if available

Time frame
At baseline evaluation
2

Genetic profile of patients with genetic dyslipidemia

Genetic profile of patients with molecular or clinical diagnosis of genetic dyslipidemia: * Prevalance (%) of patients with pathogenic/likely pathogenic variants on candidate genes * Prevalance (%) of patients with variants of uncertain significance (VUS) on candidate genes * Distribution (%) of more common variants

Time frame
At baseline evaluation

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.